Cyteph
Herston, Australia· Est.
Cyteph creates off‑the‑shelf allogeneic CMV‑specific CAR‑T therapies for solid tumours, starting with glioblastoma.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $1.5M
AI Company Overview
Cyteph creates off‑the‑shelf allogeneic CMV‑specific CAR‑T therapies for solid tumours, starting with glioblastoma.
Oncology
Technology Platform
Cyt‑ATTAC platform uses allogeneic CMV‑specific T cells as a universal carrier for CAR or TCR constructs, enabling dual‑targeting, off‑the‑shelf manufacturing and HLA‑matched patient selection.
Opportunities
Scalable off‑the‑shelf CAR‑T therapies for solid tumours, especially brain cancers, and rapid expansion of the Cyt‑ATTAC platform to additional tumour antigens.
Risk Factors
Uncertainty of efficacy in solid tumours, regulatory challenges for allogeneic cell products, and competition from larger CAR‑T developers.
Competitive Landscape
Competes with allogeneic CAR‑T firms (Allogene, Cellectis) and autologous CAR‑T leaders; differentiation lies in CMV‑specific T‑cell biology, dual‑targeting, and HLA‑matching technology.